Eisai Co. Ltd.

In News

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - simplywall.st

simplywall.st - Feb 11, 2026

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan - Eisai Co., Ltd.

Eisai Co., Ltd. - Jun 02, 2025

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China - Biogen

Biogen - Feb 09, 2026

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters

Reuters - Feb 05, 2026

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China - ACN Newswire

ACN Newswire - Feb 10, 2026

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PR Newswire

PR Newswire - Nov 25, 2025

Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:ESALF) 2025-08-05 - Seeking Alpha

Seeking Alpha - Aug 05, 2025

History of Enhancing the Company's Corporate Governance - Eisai Co., Ltd.

Eisai Co., Ltd. - May 16, 2025

Why It Might Not Make Sense To Buy Eisai Co., Ltd. (TSE:4523) For Its Upcoming Dividend - simplywall.st

simplywall.st - Sep 25, 2025

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time - ACN Newswire

ACN Newswire - Jan 21, 2026

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters

Reuters - Aug 29, 2025

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan - JCN Newswire

JCN Newswire - Feb 06, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment